{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:37:12Z","timestamp":1760747832486,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"3-5","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.jsbmb.2007.09.009","type":"journal-article","created":{"date-parts":[[2007,9,8]],"date-time":"2007-09-08T07:19:33Z","timestamp":1189235973000},"page":"267-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monoclonal antibodies in the treatment of lymphoid malignancies"],"prefix":"10.1016","volume":"108","author":[{"given":"Panagiotis","family":"Tsirigotis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theofanis","family":"Economopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2007.09.009_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib2","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanism of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low-tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib5","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib6","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib7","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib8","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated by a caspase-indepent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib9","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphism independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo-cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib11","first-page":"836","article-title":"Bonavida B: Rituximab modifies the cisplatin-mitochondrial signaling pathway resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma","volume":"8","author":"Alas","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1023\/A:1015463811683","article-title":"Cross-priming of cytotoxic T-cells promoted by apoptsis-inducing tumor cell reactive antibodies","volume":"22","author":"Selenko","year":"2002","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib13","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","article-title":"CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells","volume":"15","author":"Selenko","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<30::AID-IMMU30>3.0.CO;2-D","article-title":"Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor","volume":"29","author":"Dyall","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1172\/JCI0215640","article-title":"Immune complex mediated antigen presentation induces tumor immunity","volume":"110","author":"Rafiq","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early stage, Grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate treatment for asymptomatic advanced-stage non-Hodgkin's lymphoma: a randomized controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib19","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.V104.11.584.584","volume":"104","author":"Herold","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.V104.11.160.160","article-title":"Rituximab Added IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: to first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients","volume":"104","author":"Salles","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib22","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib26","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of 90Y-labeled ibritumonab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib27","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumonab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.exphem.2005.01.007","article-title":"T-cells armed with anti-CD3 X anti-CD20 bispecific antibody enhance killing of CD20+malignant B-cells and bypass complement-mediated rituximab resistance in vitro","volume":"33","author":"Gall","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jsbmb.2007.09.009_bib29","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood.V96.10.3544","article-title":"Therapeutic efficacy of Fc\u03b3RI\/CD64-directed bispecific antibodies in B-cell lymphoma","volume":"96","author":"Honeychurch","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jsbmb.2007.09.009_bib30","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood-2005-07-2738","article-title":"Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes","volume":"107","author":"Morecki","year":"2006","journal-title":"Blood"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076007002592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076007002592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:57:15Z","timestamp":1760734635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076007002592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":30,"journal-issue":{"issue":"3-5","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0960076007002592"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2007.09.009","relation":{},"ISSN":["0960-0760"],"issn-type":[{"type":"print","value":"0960-0760"}],"subject":[],"published":{"date-parts":[[2008,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibodies in the treatment of lymphoid malignancies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2007.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}